Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial.
about
Cutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: a systematic reviewImmunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysisInterferon beta for secondary progressive multiple sclerosisInterferon Beta for Primary Progressive Multiple SclerosisInterferon Beta for Primary Progressive Multiple SclerosisSerum S100B in primary progressive multiple sclerosis patients treated with interferon-beta-1aDisease-modifying treatments for multiple sclerosis - a review of approved medicationsEvaluation of Study and Patient Characteristics of Clinical Studies in Primary Progressive Multiple Sclerosis: A Systematic ReviewPharmacological Approaches to Delaying Disability Progression in Patients with Multiple SclerosisInterferon-beta1b treatment modulates cytokines in patients with primary progressive multiple sclerosisPrimary progressive multiple sclerosis: current therapeutic strategies and future perspectivesClinical use of brain volumetry.Cost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis: Decision analysis based on long-term clinical data and switchable treatments.Therapeutic strategies for relapsing-remitting multiple sclerosis: a special focus on reduction of grey matter damage as measured by brain atrophy.Emerging therapies in multiple sclerosis.Spinal cord imaging in multiple sclerosis.Clinical and imaging metrics for monitoring disease progression in patients with multiple sclerosis.Idiopathic inflammatory-demyelinating diseases of the central nervous system.Interferon-beta1a for the treatment of multiple sclerosis.Measuring brain atrophy in multiple sclerosis.Multiple sclerosis findings in the spinal cord.Progressive multiple sclerosis: from pathogenic mechanisms to treatment.Central nervous system atrophy and clinical status in multiple sclerosis.Impact of disease-modifying therapies on brain and spinal cord atrophy in multiple sclerosis.Primary Progressive Multiple Sclerosis: Putting Together the PuzzleRing and nodular multiple sclerosis lesions: a retrospective natural history studyTargeting progressive neuroaxonal injury: lessons from multiple sclerosis.The role of immune cells, glia and neurons in white and gray matter pathology in multiple sclerosis.Disease-modifying therapies in multiple sclerosis: an update on recent and ongoing trials and future strategies.Relapses and disability accumulation in progressive multiple sclerosisPharmacological methods to overcome IFN-beta antibody formation in the treatment of multiple sclerosis.Is inflammation important in early PPMS? a longitudinal MRI study.Emerging disease modifying therapies for multiple sclerosis.Overview of primary progressive multiple sclerosis (PPMS): similarities and differences from other forms of MS, diagnostic criteria, pros and cons of progressive diagnosis.Measurement of spinal cord atrophy in multiple sclerosis.Development of interferon-beta as a therapy for multiple sclerosis.The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosisFully automated segmentation of the cervical cord from T1-weighted MRI using PropSeg: Application to multiple sclerosis.Neutralising antibodies to IFN-beta in patients with multiple sclerosis.Interferon beta and glatiramer acetate therapy.
P2860
Q22241795-EA6AFBA5-013D-4D74-92B5-E8CB1ADE4B0BQ24202108-4D6D7958-5F1C-4741-BD74-05273F131ADEQ24203879-16C78B04-2968-4670-89EE-C277B5BD6C01Q24240620-0FDE19A0-5C1F-4C0B-A451-F3B4212905EFQ24241541-B638E2CC-533F-4CD4-9DA0-4D4C250FE7B5Q24805642-FB35F1A9-BA09-41BF-8CFF-F9975F24F08DQ26777329-D01AF0D2-DA3B-4D46-9673-D163E083FD6DQ26782408-D8929E12-E281-4D0D-AC85-4F5BC6658761Q27000269-67CC66D6-F5D1-4CED-8EF2-2EFB39675DEFQ28272201-AACC9D53-92D8-43D8-9B32-249CCEB9343CQ29030703-E60F648F-E2DC-4306-87B8-B0F4564E67A4Q30582479-9A1EACF0-3BEC-4073-BEA1-9062C1DD870BQ30651607-26776A7B-014C-461F-836F-F9EB6D6D7658Q30869048-01F68AD9-975B-4C71-BC87-B714AAB74160Q31015100-8317D8EF-0048-4C19-A0C2-3D1DD80671E6Q31027973-417A861D-E1EF-4100-A1E8-65FBF5A7F7BBQ31037055-E92C682C-F715-4731-825E-B4289582978CQ31103990-074CA0C9-0014-46A7-B93B-2A46171802C2Q31106233-3DA9641C-A87C-4E5E-B2BE-399BFBECD37FQ31108858-71E59FCB-EFA4-48BF-94A5-C624010E492EQ31128783-38A87998-26AB-4740-AB6A-B1D3B4CE4441Q31139925-12F2F3BA-87D2-4E83-9DC1-90E2F73B2BE5Q33204392-78C82209-B260-46B0-AD68-9A52D4BF9CA4Q33204393-62CD7EAB-6FDD-46A4-A228-76BF356D3085Q33365606-28ADE052-31D5-40E7-87C6-6BF9FAC1D241Q33730363-C30CDA76-A47D-4D50-B88B-048484B54BD7Q34003724-0B8F8CF3-3A02-407A-8439-E1F4E88F5C90Q34468304-D78C9161-6D10-4A15-B5DA-000AB4C29189Q35094706-DCBF3881-D092-4E65-9D15-DAA900A31525Q35106567-45FA4DC4-D163-4770-A073-346D92F60AC2Q35164752-F7A77F22-09AB-4C3F-A161-5895E098C6AEQ35489733-463A3920-3D14-4937-BBBA-B19EA4BCFC3AQ35581158-6C0A61E4-7158-4EF7-830B-12D6499754FAQ35818129-EE6780D8-64E5-4ABB-B9A4-1F5F370284EAQ35823716-313A759F-B234-4CEE-95E1-99FC38242EF7Q35967412-D079D367-92DC-4DD1-9047-0A0D68437A46Q36156669-653A6C28-637B-4618-B7DC-53845CCD1087Q36369640-72FCDEE5-A1DD-460A-854A-73FF8F313574Q36541952-349EF496-89EC-4CEF-8EB3-0D989AD5E3B9Q36568660-37D98AE7-CAC3-4AC0-98AB-9354800807B2
P2860
Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Interferon beta-1a in primary ...... randomized, controlled trial.
@en
Interferon beta-1a in primary ...... randomized, controlled trial.
@nl
type
label
Interferon beta-1a in primary ...... randomized, controlled trial.
@en
Interferon beta-1a in primary ...... randomized, controlled trial.
@nl
prefLabel
Interferon beta-1a in primary ...... randomized, controlled trial.
@en
Interferon beta-1a in primary ...... randomized, controlled trial.
@nl
P2093
P356
P1433
P1476
Interferon beta-1a in primary ...... , randomized, controlled trial
@en
P2093
A J Thompson
D H Miller
V L Stevenson
P356
10.1212/WNL.60.1.44
P407
P50
P577
2003-01-01T00:00:00Z